论文部分内容阅读
Molecular or personalized medicine is the future of patient management and molecular imaging plays a key role towards this goal.Angiogenesis, the formation of new blood vessels, is a critical process in both physiological development and pathological processes such as tumor progression and cardiovascular diseases.In this talk,I will present the development of molecular imaging probes targeting angiogenesis focusing on two major targets: VEGFR-2 (flk-1/KDR) and integrin αvβ3.These imaging probes are based on peptides, proteins, antibodies, and nanoparticles (quantum dots and single-walled carbon nanotubes).Recently, nanoplatform-based molecular imaging has emerged as an interdisciplinary field which involves chemistry, engineering, biology, and medicine.Multifunctionality is the key advantage of nanoplatform over traditional approaches.Targeting ligands, imaging labels, therapeutic drugs, and many other agents can all be integrated into the nanoplatform to allow for targeted molecular imaging and molecular therapy.In this presentation, I will give several examples using quantum dots and single-walled carbon tubes as nanoplatforms for targeted molecular imaging in living subjects.Quantitative positron emission tomography (PET) imaging of VEGFR expression in living animals, as well as the use of multimodality imaging techniques (PET, magnetic resonance imaging, and bioluminescence) to non-invasively monitor VEGFR-2-targeted treatment efficacy, will also be presented.